Veradermics, Inc Increase (Decrease) in Accrued Interest Receivable, Net
Veradermics, Inc (MANE) reported Increase (Decrease) in Accrued Interest Receivable, Net of $2.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-08-11
- Veradermics, Inc increase (decrease) in accrued interest receivable, net for the quarter ending 2026-06-30 was $1.28M.
- Veradermics, Inc increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was $1.50M.
- Veradermics, Inc increase (decrease) in accrued interest receivable, net for the quarter ending 2025-06-30 was $0.00.
- Veradermics, Inc increase (decrease) in accrued interest receivable, net for the quarter ending 2025-03-31 was $0.00.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month |
|---|---|---|
| 2026-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $2.78M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.50M 10-Q · filed 2026-05-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |